Abstract: Disclosed are ligands comprising a first polypeptide domain having a binding site with binding specificity for a first cell surface target and a second polypeptide domain having a binding site for a second cell surface target, wherein each target are different and on the same cell. In some embodiments, the ligands described further comprise a toxin. In other embodiments, the ligands further comprise half-life extending moieties. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described.

Abstract: A key fob for a vehicle has a first end that is used as a key for insertion into a vehicle ignition receptacle and a second end that defines an opening for internal storage of a separate, removable key. While the key fob will remotely unlock the vehicle doors and start the vehicle engine when turned in the vehicle ignition, the removable key is an auxiliary, mechanical access key that may be used on door locks and interior storage compartments. The key fob will not unlock interior storage compartments and the removable key will not sustain operation of the vehicle engine.

Abstract: Systems and methods for locating digital media content. The systems and methods include receiving search terms from a client device through a single interface, searching a plurality of digital media content providers for digital media content using the search terms to obtain search results, sorting and organizing the search results, and returning the search results to the client device through the single interface.

Abstract: Drug fusions and conjugates that contain an incretin therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The conjugates and fusion have a longer in vivo half life in comparison with the unconjugated or unfused therapeutic or diagnostic agent.

Abstract: Disclosed is the use of an antagonist of Interleukin 1 receptor type 1 (IL-1R1) for the manufacture of a medicament treating, preventing or suppressing lung inflammation or a respiratory disease. In some embodiments of the described invention, the medicament is for local administration to pulmonary tissue. Also disclosed are methods for treating lung inflammation or a respiratory disease.

Abstract: Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described.

Abstract: The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity.

Abstract: The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity.

Abstract: A key fob for a vehicle has a first end that is used as a key for insertion into a vehicle ignition receptacle and a second end that defines an opening for internal storage of a separate, removable key. While the key fob will remotely unlock the vehicle doors and start the vehicle engine when turned in the vehicle ignition, the removable key is an auxiliary, mechanical access key that may be used on door locks and interior storage compartments. The key fob will not unlock interior storage compartments and the removable key will not sustain operation of the vehicle engine.

Abstract: The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity.

Abstract: Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described.

Abstract: The invention provides methods for treating inflammatory diseases (e.g., chronic inflammatory diseases) comprising administering an antagonist of Tumor Necrosis Factor Receptor 1. The invention also provides antagonists of Tumor Necrosis Factor Receptor 1, such as ligands that contain an immunoglobulin single variable domain or domain antibody (dAb) monomer that binds Tumor Necrosis Factor Receptor 1, and methods of using the ligands. Also provided are nucleic acids encoding the ligands, recombinant host cells and methods for preparing the ligands.

Abstract: A multiplexer is constructed, which has a stable volume over its thermal operating range. A composite material is used that utilizes a fabric having fibers of opposing coefficients of thermal expansion. Such fibers are assembled at an angle to each other so that resulting expansion and contractions counter act and cancel. One of the fibers is selected for its high thermal conductivity and extends over the length of the multiplexer to form a heat dissipating path.

Abstract: A computer system comprising a casing enclosing a computer core unit and a latching system including a handle mechanism for removably securing the computer core unit within the casing; wherein the handle mechanism is configured in a first position for securing the core unit into the casing and in a second position for removing the core unit from the casing.

Abstract: A heat removal system for a computer comprising a casing enclosing a hard drive and a microprocessor, the casing including an opening in an exterior surface thereof; a heat sink positioned between the hard drive and the microprocessor, the heat sink being aligned with the opening in the casing so as to form a thermal chimney; and a spreader plate disposed between the microprocessor and the heat sink, the spreader plate conducting heat from the microprocessor to the heat sink.

Abstract: A device for performing immunoassays which has an external housing, a sample container provided with reagents that can be inserted into the external housing, a material container for an absorbent material and membrane-bound antibody or antigen that can be inserted into the sample container, a holder for the material container that can be mounted on the external container, and a spacer that can join the holder and the sample container. When the spacer is in place, the absorbent material is held above the portion of the sample container that holds the sample and when the spacer is removed, the absorbent material is lowered into the sample-containing portion of the sample container. The external housing may also include a container for developer.